一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Accounts of Chemical Research >>article
Accounts of Chemical Research

Accounts of Chemical Research

IF: 16.4
Download PDF

Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.

Published:1 October 2021 DOI: 10.1111/1744-9987.13609 PMID: 33200512
Tadao Akizawa, Yusuke Yamaguchi, Yoshikatsu Majikawa, Michael Reusch

Abstract

Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease (CKD). Emerging evidence suggests that roxadustat may be beneficial for patients who inadequately respond to erythropoiesis-stimulating agents (ESAs). This post-hoc analysis of a Japanese, double-blind, randomized, phase 3 study in hemodialysis-dependent CKD patients treated with traditional ESAs assessed the impact of factors associated with ESA hyporesponsiveness on roxadustat and darbepoetin alfa (DA) doses required to maintain target hemoglobin. Endpoints included mean of average doses of roxadustat and DA per administration in the last 6?weeks (AAD/6W) by prior ESA-resistance index (ERI), iron repletion (transferrin saturation; ferritin), and high-sensitivity C-reactive protein (hs-CRP). Of 415 enrolled patients, 303 were randomized (roxadustat, n?=?151; DA, n?=?152). Weight-adjusted AAD/6W increased with increasing ERI for roxadustat (ERI <3.3, 0.89?mg/kg; ERI ≥8.4, 1.51?mg/kg) and DA (ERI <3.3, 0.26?μg/kg; ERI ≥8.4, 0.91?μg/kg); the weight-adjusted AAD/6W relative to within-arm mean AAD/6W showed a trend toward increased DA doses for the ERI ≥8.4 category (P?=?.089). AAD/6W remained stable for roxadustat but increased for DA with decreasing baseline iron repletion markers. The relationship between roxadustat doses and end of treatment (EoT) hs-CRP was not significant (estimated slope, -0.494; P?=?.814); a trend toward increased DA doses was observed with increasing EoT hs-CRP (estimated slope, 2.973; P?=?.075). Roxadustat doses required to maintain target hemoglobin appear to be less affected by factors that underlie ESA hyporesponsiveness, relative to DA; roxadustat may be beneficial for patients hyporesponsive to ESAs.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Roxadustat 808118-40-3 C19H16N2O5 416 suppliers $28.00-$6800.00
darbepoetin alfa 209810-58-2 3 suppliers Inquiry

Similar articles

IF:3.2

Roxadustat for Patients with Post-transplant Anemia: A Narrative Review

Kidney Diseases Xiaoxiao Tang, Fei Liu,etc Published: 10 November 2023
IF:5.4

Roxadustat: Not just for anemia.

ACS Applied Energy Materials Xiaoyu Zhu, Lili Jiang,etc Published: 29 August 2022
IF:16.4

Efficacy and Safety of Microsomal Ferric Pyrophosphate Supplement for Iron Deficiency Anemia in Pregnancy

Accounts of Chemical Research Ankita Srivastav, Shilpa Kshirsagar,etc Published: 28 March 2024
徐汇区| 文安县| 辉南县| 平武县| 察隅县| 南岸区| 托里县| 开江县| 泰宁县| 巍山| 新乡市| 新晃| 焦作市| 合川市| 丽江市| 兰坪| 杨浦区| 兴山县| 凤庆县| 巴中市| 安宁市| 镇雄县| 虞城县| 高安市| 万盛区| 武陟县| 方山县| 沙河市| 建水县| 治县。| 建始县| 灌云县| 沙雅县| 阜南县| 扶绥县| 朔州市| 定陶县| 叶城县| 三门县| 安化县| 镇坪县|